Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | ACACA | Q13085 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 6/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19067579 | 0.94 | HTR7 (0.37) | ACACBACACASMN1; SMN2HTR7TMEM97 | |
| SCHEMBL14222091 | 0.80 | ACACB (0.33) | ACACBACACALMNA | |
| SCHEMBL9963431 | 0.76 | CYP2D6 (0.34) | ACACBACACAHTR7LMNA | |
| SCHEMBL1514705 | 0.75 | ACACB (0.39) | ACACBACACAHTR7 | |
| SCHEMBL16150152 | 0.74 | HTR7 (0.36) | HTR7TMEM97 | |
| SCHEMBL16150655 | 0.72 | HTR7 (0.38) | HTR7TMEM97 | |
| SCHEMBL24909383 | 0.72 | HTR7 (0.33) | HTR7TMEM97 | |
| SCHEMBL441723 | 0.70 | — | — | |
| SCHEMBL24909369 | 0.69 | HTR7 (0.36) | HTR7TMEM97 | |
| SCHEMBL19786710 | 0.69 | HTR7 (0.44) | HTR7TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220505-B2 | 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-01-11 | — | — | US | disclosed |
| US-20200331915-A1 | 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2020-10-22 | — | — | US | disclosed |
| US-4430131-A | Polyurethane binders | HER MAJESTY THE QUEEN IN RIGHT OF CANADA (CA) | 1984-02-07 | — | — | US | disclosed |
| US-4415728-A | BINDERS FOR SOLID PROPELLANTS | HER MAJESTY THE QUEEN IN RIGHT OF CANADA (CA) | 1983-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331915-A1 | 5-HYDROXYTRYPTAMINE RECEPTOR 7 MODULATORS AND THEIR USE AS THERAPEUTIC AGENTS | HTR7, HTR6, HTR5A | ACACB 3665/4885ACACA 3822/4885SMN1; SMN2 2420/4885 |
| US-11220505-B2 | 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents | HTR7, HTR6, HTR5A | ACACB 3665/4885ACACA 3822/4885SMN1; SMN2 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.